Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)

Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)

Most if not all vaccine candidates developed to combat COVID-19 due to SARS-CoV-2 infection are administered parenterally. As SARS-CoV-2 is transmitted through infectious respiratory fluids, vaccine-induced mucosal immunity could provide an important contribution to control this pandemic. ChAd-SARS-...

Full description

Bibliographic Details
Main Authors: Raju Sunagar, Sai D. Prasad, Raches Ella, Krishna Mohan Vadrevu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2
COVID-19 vaccine
BBV154
ChAd vaccine
intranasal vaccine
mucosal vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1063679/full

Similar Items

Similar Items